Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Clinical Study Evaluating the Efficacy and Safety of AK102 in Patients With Primary Hypercholesterolemia and Mixed Hyperlipidemia

Next Previous
Search
Trial Profile

A Phase 3 Clinical Study Evaluating the Efficacy and Safety of AK102 in Patients With Primary Hypercholesterolemia and Mixed Hyperlipidemia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ebronucimab (Primary)
  • Indications Hypercholesterolaemia; Hyperlipidaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Akeso Biopharma

    • Most Recent Events

    • 04 Mar 2025 Status changed from active, no longer recruiting to completed.
    • 30 Sep 2024 According to Akeso Biopharma media release, National Medical Products Administration (NMPA) of China has approved the new drug application (NDA) of (ebronucimab, PCSK9) for the treatment of primary hypercholesterolemia and mixed hyperlipidemia and heterozygous familial hypercholesterolaemia (HeFH), based on results from this study.
    • 01 Sep 2024 Results published in the Pharmacological Research

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top